🔎 Trials Near Me

Akèy › Kansè Vezik ki pa envazif miskilè › Texas › Austin

Etid klinik pou Kansè Vezik ki pa envazif miskilè nan Austin, TX

6 etid pou Kansè Vezik ki pa envazif miskilè ap chèche patisipan nan sit nan ak bò kote Austin (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

Ap rekriteFaz 2
  • Texas Oncology-Austin Central ( Site 0107), Austin
  • Urology Austin, PLLC ( Site 0109), Austin
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06833073

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Ap rekriteFaz 2
  • Urology Austin, Austin
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06995677

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

Ap rekriteFaz 3
  • Texas Oncology-Austin, Austin
  • Urology Austin, Austin
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06919965

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Ap rekriteFaz 2
  • Urology Austin, LLC, Austin
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT05951179

Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC)

Ap rekriteEtid obsèvasyon
  • Natera, Inc., Austin
Laj 18 ak plis · Tout sèks · Mizajou Aug 13, 2026 · NCT07763197

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Ap rekriteFaz 1/2
  • Urology Austin, Austin
Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT04752722

Etid Kansè Vezik ki pa envazif miskilè nan lòt vil

Lòt etid nan Austin

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.